Summary
This narrative review, published in Nature Reviews Neurology, examines the application of next-generation sequencing to Charcot–Marie–Tooth disease diagnosis, a genetically heterogeneous peripheral neuropathy. The authors discuss advances in sequencing capacity and variant interpretation alongside persistent challenges in translating genomic findings into clinical care, including the handling of variants of uncertain significance and the need for improved phenotype–genotype correlation. As suggested by the journal scope and publication year, the paper likely advocates for standardised clinical protocols and multi-disciplinary approaches to maximise diagnostic utility whilst managing data interpretation complexity.
UK applicability
The clinical diagnostic and genomic interpretation frameworks discussed are directly applicable to United Kingdom NHS genetics services and neurological centres diagnosing inherited peripheral neuropathies. The paper's emphasis on standardised variant classification and phenotypic characterisation aligns with current UK Rare Diseases policy and precision medicine initiatives.
Key measures
Diagnostic yield of NGS platforms; variants of uncertain significance; clinical correlation with genotype; cost-effectiveness of sequencing strategies
Outcomes reported
The paper reviews opportunities and challenges in applying next-generation sequencing (NGS) technologies to diagnose and characterise genetic variants in Charcot–Marie–Tooth disease. It addresses methodological advances, interpretation of genomic data, and clinical implementation barriers in a monogenic neurological disorder.
Topic tags
Dig deeper with Pulse AI.
Pulse AI has read the whole catalogue. Ask about this record, its theme, or how the findings apply to UK farming and policy — every answer cites the underlying studies.